Profiling on Altered Productions of Cytokines or Chemokines from THP-1 Cell Line Following in Vitro Exposure to Cyclophosphamide, Cyclosporine, Dexamethasone, or Tacrolimus, Representative Immunosuppressants

Manju Acharya; JiHun Jo (조지훈); Anju Mahrjan; Ravi Gautam; Daeun Lee (이다은); Kim Chang Yul (김창열); Yong Heo (허용)

doi:10.23032/jaae.2020.14.1.003

Profiling on Altered Productions of Cytokines or Chemokines from THP-1 Cell Line Following in Vitro Exposure to Cyclophosphamide, Cyclosporine, Dexamethasone, or Tacrolimus, Representative Immunosuppressants

Journal of Alternatives to Animal Experiments
Abbr : J Altern Anim Exp
2020, 14(1), pp.23-30
DOI : 10.23032/jaae.2020.14.1.003
Publisher : Korean Society for Alternatives to Animal Experiments
Research Area : Medicine and Pharmacy > Veterinary > Basic Veterinary Medicine > Laboratory Animal Medicine
Received : December 3, 2020
Accepted : December 14, 2020
Published : December 30, 2020

Manju Acharya ¹, JiHun Jo ², Anju Mahrjan ², Ravi Gautam ¹, Daeun Lee ², Kim Chang Yul ², Yong Heo ²

¹대구가톨릭대학교 산업보건학과
²대구가톨릭대학교

Candidate

ABSTRACT

Although immune suppressive drugs have contributed for the cancer chemotherapy, organ transplant, but their therapeutic efficacy is limited. This study aims to evaluate the immunological modulations induced by four representative immunosuppressive on THP-1 cell line. 75% cell viabilities were determined and four test concentrations, 0.01X, 0.1X, 0.5X, and vehicle control were chosen. Culture supernatants were collected at 24 h after lipopolysaccharide (LPS1 ㎍/㎖) activation in the presence of test substances. 27 target cytokines were measured through luminex system and relative cytokine production levels (RCPLs,%) were calculated. Cytokines with the RCPL below 100% at all the three concentrations were 21 including IL-1beta, -1ra, -2, -4, -5, -6, -7, -9, -10, -12, -13, -15, -17, Eotaxin, FGF-basic, GM-CSF, IFNγ, IP-10, MCP-1α, PDGF-BB, and VEGF in dexamethasone-treated cells. Concerning on cyclophosphamide, the RCPLs on 11 cytokines were less than 100% at all the 3 concentrations. Treatment of cyclosporine demonstrated 10 cytokines with below 100% RCPL at all the 3 concentrations. The RCPLs below 100% were observed with 22 cytokines including IL-1β, -1ra, -2, -4, -5, -6, -7, -9, -12, -13, -15, -17, Eotaxin, GFG-basic, G-CSF, GM-CSF, IFNγ, MCP-1, MIP-1α, PDGF-BB, TNFα, a nd VEGF from THP-1 cells t reated w ith tacrolimus a t all the 3 concentrations. The present study indicates that tacrolimus and dexamethasone are stronger immunosuppressants than cyclophosphamide and cyclosporine on THP-1 cell line.

KEYWORDS

Immunotoxicants, immunosuppression, cytokines, chemokines, THP-1 cell line

Citation status

* References for papers published after 2023 are currently being built.

[journal] Akdis M / 2016 / Interleukins(from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α : receptors, functions, and roles in diseases / J. Allergy Clin. Immunol 138 : 984~1010

[journal] Ahlmann M / 2016 / The effect of cyclophosphamide on the immune system : implications for clinical cancer therapy / Cancer Chemother. Pharmacol 78 : 661~671

[journal] Bianchi M / 2000 / Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids / PNAS 97 : 9573~9578

[journal] Brazelton TR / 1996 / Molecular mechanisms of action of new xenobiotic immunosuppressive drugs : tacrolimus(FK506), sirolimus(rapamycin), mycophenolate mofetil and leflunomide / Curr. Opin. Immunol 8 : 710~720

[journal] Cavallasca JA / 2015 / Severe infections in patients with autoimmune disease treated with cyclophosphamide / Reumatol. Clin 11 : 221~223

[journal] Cilião HL / 2015 / Cytotoxic and genotoxic effects of high concentrations of the immunosuppressive drugs cyclosporine and tacrolimus in MRC-5 cells / Exp. Toxicol. Pathol 67 : 179~187

[journal] Coecke S / 2005 / Guidance on good cell culture practice. A report of the second ECVAM task force on good cell culture practice / ATLA 33 : 1~27

[journal] Diehl R / 2017 / Immunosuppression for in vivo research : state-of-the-art protocols and experimental approaches / Cell. Mol. Immunol 14 : 146~179

[journal] Gennari A / 2005 / The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop / J. Immunotoxicol 2 : 61~83

[journal] Giles AJ / 2018 / Dexamethasone-induced immunosuppression : mechanisms and implications for immunotherapy / J. ImmunoTher. Cancer 6 : 51~

[journal] Gong JH / 2020 / Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling / Cancer Biol. Ther 21 : 332~343

[journal] Hartung T / 2013 / Immunotoxicology : Challenges in the 21st century and in vitro opportunities / ALTEX 30 : 411~426

[journal] Hinton DM. / 1995 / Immunotoxicity testing applied to direct food and colour additives : US FDA’Redbook II’ guidelines / Hum. Exp. Toxicol 14 : 143~145

[journal] Hirano T. / 2007 / Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine / Int. Immunopharmacol 7 : 3~22

[journal] Lankveld DP / 2010 / In Vitro testing for Direct Immunotoxicity : State of the Art / Methods Mol. Biol 598 : 401~423

[journal] Matsuda S / 2000 / Mechanisms of action of cyclosporine / Immunopharmacology 47 : 119~125

[journal] Naesens M / 2009 / Calcineurin inhibitor nephrotoxicity / Clin. J. Am. Soc. Nephrol 4 : 481~508

[journal] Pointon JC / 2010 / Thalidomide enhances cyclophosphamide and dexamethasone mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells / Oncol. Rep 24 : 1315~1321

[journal] Shoughy SS / 2016 / Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis / Clin. Ophthalmol 10 : 643~647

[journal] Tongu M / 2010 / Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma / Cancer Immunol. Immunother 59 : 769~777

[journal] Wang H / 2004 / Dexamethasone as a chemoprotectant in cancer chemotherapy : hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine / Cancer Chemother. Pharmacol 53 : 459~467

[journal] Wang H / 2007 / Dexamethasone as a chemosensitizer for breast cancer chemotherapy : potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics / Int. J. Oncol 30 : 947~953

[journal] Winkelstein A / 1973 / Mechanism of Immunosuppression : Effects of Cyclophosphamide on Cellular Immunity / Blood 41 : 273~284

[journal] Zhai J / 2011 / Tacrolimus in the treatment of ocular diseases / BioDrugs 25 : 89~103

[journal] Zhang W / 2019 / Recent topics on the mechanisms of immunosuppressive therapy-related neurotoxicities / Int. J. Mol. Sci 20 : 3210~

KJCKorea
Journal Central

Journal of Alternatives to Animal Experiments 2023 KCI Impact Factor : 0.07

Profiling on Altered Productions of Cytokines or Chemokines from THP-1 Cell Line Following in Vitro Exposure to Cyclophosphamide, Cyclosporine, Dexamethasone, or Tacrolimus, Representative Immunosuppressants

ABSTRACT

KEYWORDS

Citation status

* References for papers published after 2023 are currently being built.

Journal of Alternatives to Animal Experiments 2023 KCI Impact Factor : 0.07

Profiling on Altered Productions of Cytokines or Chemokines from THP-1 Cell Line Following in Vitro Exposure to Cyclophosphamide, Cyclosporine, Dexamethasone, or Tacrolimus, Representative Immunosuppressants

ABSTRACT

KEYWORDS

Statistics

Tools

Issue List

Citation status

KCI Citation Counts (0)

REFERENCES (25) * References for papers published after 2023 are currently being built.

Search PDF

Citation

* References for papers published after 2023 are currently being built.